Search results
Showing 121 to 135 of 456 results for blood monitoring
Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
Awaiting development Reference number: GID-HTG10536 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease (TA20)
Evidence-based recommendations on the use of riluzole (Rilutek) for treating motor neurone disease (MND).
This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.
View quality statements for QS156Show all sections
Sections for QS156
- Quality statements
- Quality statement 1: Medicines reconciliation
- Quality statement 2: Second-stage health assessment
- Quality statement 3: Blood-borne viruses and sexually transmitted infections
- Quality statement 4: Lead care coordinator
- Quality statement 5: Medicines on transfer or discharge
- Update information
- About this quality standard
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.
Bipolar, schizophrenia and other psychoses: annual blood glucose or HbA1c (IND159)
This indicator covers the percentage of patients aged 18 years and over with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood glucose or HbA1c in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM130
Hypertension: confirming diagnosis with HBPM or ABPM (IND115)
This indicator covers the percentage of patients with a new diagnosis of hypertension (diagnosed on or after 1 April 2014) which has been confirmed by ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) in the 3 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM66
Attention deficit hyperactivity disorder: diagnosis and management (NG87)
This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.
Dexcom G6 for real-time continuous glucose monitoring (MIB233)
NICE has developed a medtech innovation briefing (MIB) on Dexcom G6 for real-time continuous glucose monitoring .
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.
Show all sections
This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.